News Release

Yamanouchi Pharmaceutical Co., Ltd.

Yamanouchi Pharmaceutical Co., Ltd. and Glaxo Wellcome K.K. initiate research collaboration study on identifying potential drug target genes

June 7, 2000

Yamanouchi Pharmaceutical Co., Ltd. (President: Toichi Takenaka) and Glaxo Wellcome K.K. (President: Marc Dunoyer) have initiated a research collaborative study to identify drug target genes, with an aim to find future new treatments against certain diseases. This study will be carried out with two domestic universities, Tokyo Women's Medical University and Jichi Medical School. The universities are responsible for collecting clinical samples and the pharmaceutical companies are to analyse and identify genes that are possibly related to the diseases. The collaborative study has been reviewed and approved by the universities' ethics committees.

Yamanouchi Pharmaceutical Co., Ltd. and Glaxo Wellcome K.K. have been in a technical tie-up on gene expression analysis technologies since November 1999, exchanging information which enable instant analysis of several hundred genes by a filter of about the size of a post card called "Big Chip". In the collaborative study announced today, the two companies undertake gene expression analysis using Big Chip and process information gained from clinical and gene expression data through bioinformatic technology.

Yamanouchi Pharmaceutical Co., Ltd. considers genomic science as one of the major tools for drug discovery research, making efforts to further speed up the process of analysing and identifying gene functions and their relationship with various diseases. Strategic alliances with academia and venture companies are actively held as well, signing a joint research contract this February with Hospital for Joint Diseases, New York University Medical Center, USA, focusing in the identification of genes related to osteoarthritis. Yamanouchi Pharmaceutical Co., Ltd. plans to expand its strength in genomic research both internally and externally.

Tsukuba Research Laboratories, Glaxo Wellcome K.K. is one of the Glaxo Wellcome's nine worldwide research centres together with those in the UK, USA and Italy. Disease areas being researched at Tsukuba include cancer, respiratory, central nervous system disorders and dermatology. An integrated approach is taken in drug discovery research, utilising new technologies such as gene analysis, bioinformatics, high throughput screening, combinatorial chemistry and proteomics.